Home › Research › Tau biomarkers
Avanços em biomarcadores plasmáticos e do líquido cefalorraquidiano para a detecção precoce da doença de Alzheimer
Lemuel Kalil da Silva Vieira, Giulia Germano de Azevedo Silva, Isabella Ayka Melo Oti, Tereza Cristina Barbosa Ribeiro do Vale, Aneybh Oliveira Gurgel, Renata Alcântara Calixto, Dominique Cardoso Passos Mesquita, Isadora Fontenelle Carneiro de Castro et al.. Brazilian Journal of Health Review, 2025-01-14
Topic: Amyloid, tau and blood-test diagnosis
A Doença de Alzheimer (DA) é a principal causa de demência em idosos, causada pelo acúmulo de β-amiloide e emaranhados neurofibrilares no cérebro. Novas terapias, como anticorpos monoclonais, destacam a importância de identificar a doença cedo. O futuro do tratamento da DA depende de biomarcadores acessíveis e não invasivos. Este estudo revisou a literatura sobre biomarcadores na Doença de Alzheimer (DA) em bases de dados de 2021 a 2024. Incluiu estudos que avaliaram biomarcadores sanguíneos, como β-amiloide e tau, com desfechos clínicos. A busca nas bases de dados resultou em 351 artigos. Após a aplicação dos critérios de elegibilidade, 6 artigos foram analisados e 4 selecionados. A pesquisa destacou a importância de biomarcadores como p-tau e β-amiloide no diagnóstico precoce e acompanhamento da Doença de Alzheimer (DA). O uso de algoritmos e biomarcadores, como GFAP e YKL-40, mostrou potencial para reduzir procedimentos invasivos e melhorar a identificação precoce da doença, facilitando intervenções terapêuticas e ensaios clínicos. Contudo, ainda há desafios éticos e a necessidade de mais pesquisas para validar o uso desses biomarcadores na prática clínica. Biomarcadores como p-tau e GFAP são fundamentais no diagnóstico precoce e monitoramento da Doença de Alzheimer, ajudando a identificar riscos e possibilitar intervenções preventivas. Mais pesquisas são necessárias para validar esses biomarcadores na prática clínica.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Vieira, L. K. d. S., Silva, G. G. d. A., Oti, I. A. M., Vale, T. C. B. R. d., Gurgel, A. O., Calixto, R. A., et al. (2025). Avanços em biomarcadores plasmáticos e do líquido cefalorraquidiano para a detecção precoce da doença de Alzheimer. Brazilian Journal of Health Review. https://doi.org/10.34119/bjhrv8n1-181
Vancouver
Vieira LKdS, Silva GGdA, Oti IAM, Vale TCBRd, Gurgel AO, Calixto RA, et al. Avanços em biomarcadores plasmáticos e do líquido cefalorraquidiano para a detecção precoce da doença de Alzheimer. Brazilian Journal of Health Review. 2025. doi:10.34119/bjhrv8n1-181.
BibTeX
@article{vieira2025-f308d829,
author = {Vieira, Lemuel Kalil da Silva and Silva, Giulia Germano de Azevedo and Oti, Isabella Ayka Melo and Vale, Tereza Cristina Barbosa Ribeiro do and Gurgel, Aneybh Oliveira and Calixto, Renata Alcântara and Mesquita, Dominique Cardoso Passos and de Castro, Isadora Fontenelle Carneiro and others},
title = {{Avanços em biomarcadores plasmáticos e do líquido cefalorraquidiano para a detecção precoce da doença de Alzheimer}},
journal = {Brazilian Journal of Health Review},
year = {2025},
doi = {10.34119/bjhrv8n1-181},
url = {https://doi.org/10.34119/bjhrv8n1-181}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- A pesquisa destacou a importância de biomarcadores como p-tau e β-amiloide no diagnóstico precoce e acompanhamento da Doença de Alzheimer (DA).
- O uso de algoritmos e biomarcadores, como GFAP e YKL-40, mostrou potencial para reduzir procedimentos invasivos e melhorar a identificação precoce da doença, facilitando intervenções terapêuticas e ensaios clínicos.
- Contudo, ainda há desafios éticos e a necessidade de mais pesquisas para validar o uso desses biomarcadores na prática clínica.
- Biomarcadores como p-tau e GFAP são fundamentais no diagnóstico precoce e monitoramento da Doença de Alzheimer, ajudando a identificar riscos e possibilitar intervenções preventivas.
- Mais pesquisas são necessárias para validar esses biomarcadores na prática clínica.
Why it matters
This review of 6 studies found that blood biomarkers such as p-tau and β-amyloid are important for early diagnosis and monitoring of Alzheimer's disease, and that algorithms using markers like GFAP and YKL-40 may reduce the need for invasive procedures. The authors note ethical challenges remain and more research is needed before these biomarkers can be used in routine clinical practice.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 27/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 26 of the 96 points we could judge it on, which is 27 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brazilian Journal of Health Review) |
| Journal's citation record | 0 / 4 | Brazilian Journal of Health Review: journal h-index 26 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 0 / 3 | Universidade de Pernambuco: institution h-index 171 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 26 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 26 of the 96 points we could judge it on is 27 out of 100. |
| Total | 27 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Tau biomarkers
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.